Literature DB >> 8608360

A comparison of the effectiveness and cost of treatment for vertebral fractures in women.

R M Francis1, F H Anderson, D J Torgerson.   

Abstract

Of the treatments available for the management of established vertebral osteoporosis, hormone replacement therapy (HRT), intermittent cyclical etidronate therapy and salmon calcitonin have been shown in randomized, controlled trials to reduce the risk of further vertebral fractures. In order to compare the cost effectiveness of these different treatments we examined the cost and efficacy of each treatment using previously published data. HRT, cyclical etidronate and salmon calcitonin all decrease the incidence of further vertebral fracture by 50-60%. Estimation of the cost per vertebral fracture averted therefore reflects the underlying cost of medication, with HRT costing 138-680 pounds per fracture averted compared with 1880 pound for cyclical etidronate therapy and 9075-25 013 pounds for salmon calcitonin therapy. HRT is therefore the treatment of choice for post-menopausal women with osteoporosis, particularly as it may also decrease the risk of ischaemic heart disease. Although salmon calcitonin appears as effective as the other treatments, it is considerably more expensive, so should be reserved for situations where HRT and cyclical etidronate are inappropriate.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8608360     DOI: 10.1093/rheumatology/34.12.1167

Source DB:  PubMed          Journal:  Br J Rheumatol        ISSN: 0263-7103


  6 in total

Review 1.  Intranasal salcatonin (salmon calcitonin). A review of its pharmacological properties and role in the management of postmenopausal osteoporosis.

Authors:  G L Plosker; D McTavish
Journal:  Drugs Aging       Date:  1996-05       Impact factor: 3.923

Review 2.  Economic evaluations of interventions for the prevention and treatment of osteoporosis: a structured review of the literature.

Authors:  Rachael L Fleurence; Cynthia P Iglesias; David J Torgerson
Journal:  Osteoporos Int       Date:  2005-06-25       Impact factor: 4.507

3.  Does the funding source influence the results in economic evaluations? A case study in bisphosphonates for the treatment of osteoporosis.

Authors:  Rachael L Fleurence; D Eldon Spackman; Christopher Hollenbeak
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

Review 4.  Management of established osteoporosis.

Authors:  R M Francis
Journal:  Br J Clin Pharmacol       Date:  1998-02       Impact factor: 4.335

Review 5.  Assessing generalisability in model-based economic evaluation studies: a structured review in osteoporosis.

Authors:  Hege Urdahl; Andrea Manca; Mark J Sculpher
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

Review 6.  The cost effectiveness of bisphosphonates for the prevention and treatment of osteoporosis: a structured review of the literature.

Authors:  Rachael L Fleurence; Cynthia P Iglesias; Jeanene M Johnson
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.